{"DataElement":{"publicId":"6293819","version":"1","preferredName":"Latent Indolent Non-Hodgkin Lymphoma Diagnosis Name","preferredDefinition":"The name to describe the diagnosed underlying non-Hodgkin's lymphoma with an indolent clinical course.","longName":"LAT_INHL_NM","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"6290668","version":"1","preferredName":"Latent Indolent Non-Hodgkin Lymphoma Diagnosis","preferredDefinition":"Describes a condition that is present but not active or causing symptoms._A non-Hodgkin lymphoma with an indolent clinical course. Representative examples include grade 1 and grade 2 follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"6290666v1.0:2239981v1.0","context":"Theradex","contextVersion":"1","ObjectClass":{"publicId":"6290666","version":"1","preferredName":"Latent Indolent Non-Hodgkin Lymphoma","preferredDefinition":"Describes a condition that is present but not active or causing symptoms.:A non-Hodgkin lymphoma with an indolent clinical course. Representative examples include grade 1 and grade 2 follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma.","longName":"C28225:C8504","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Latent","conceptCode":"C28225","definition":"Describes a condition that is present but not active or causing symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indolent Non-Hodgkin Lymphoma","conceptCode":"C8504","definition":"A non-Hodgkin lymphoma with an indolent clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C66754D-717B-0B03-E053-F662850AA479","latestVersionIndicator":"Yes","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-17","modifiedBy":"ONEDATA","dateModified":"2018-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2239981","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-1C71-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-26","modifiedBy":"ONEDATA","dateModified":"2005-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C66754D-7189-0B03-E053-F662850AA479","latestVersionIndicator":"Yes","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-17","modifiedBy":"TAYLORT","dateModified":"2018-05-21","changeDescription":"5/17/18 tt/10126 & 10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6293818","version":"1","preferredName":"Indolent Non-Hodgkin Lymphoma Name","preferredDefinition":"A non-Hodgkin lymphoma with an indolent clinical course. Representative examples include grade 1 and grade 2 follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma._The words or language units by which a thing is known.","longName":"6293818v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C663E7A-09C1-0AFE-E053-F662850AD265","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-17","modifiedBy":"ONEDATA","dateModified":"2018-05-17","deletedIndicator":"No"},{"value":"Chronic lymphocytic leukemia/small lymphocytic lymphoma","valueDescription":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","ValueMeaning":{"publicId":"2837954","version":"1","preferredName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","longName":"2837954","preferredDefinition":"An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","conceptCode":"C27911","definition":"An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6282862D-CE74-EC8D-E040-BB89AD434A77","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C663E7A-09EA-0AFE-E053-F662850AD265","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-17","modifiedBy":"ONEDATA","dateModified":"2018-05-17","deletedIndicator":"No"},{"value":"Marginal zone lymphoma","valueDescription":"Marginal Zone Lymphoma","ValueMeaning":{"publicId":"3251331","version":"1","preferredName":"Marginal Zone Lymphoma","longName":"3251331","preferredDefinition":"A usually indolent mature B-cell lymphoma, arising from the marginal zone of lymphoid tissues.  It is characterized by the presence of small to medium sized atypical lymphocytes.  It comprises three entities, according to the anatomic sites involved: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which affects extranodal sites (most often stomach, lung, skin, and ocular adnexa); nodal marginal zone B-cell lymphoma, which affects lymph nodes without evidence of extranodal disease; and splenic marginal zone B-cell lymphoma, which affects the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marginal Zone Lymphoma","conceptCode":"C4341","definition":"A usually indolent mature B-cell lymphoma, arising from the marginal zone of lymphoid tissues.  It is characterized by the presence of small to medium sized atypical lymphocytes.  It comprises three entities, according to the anatomic sites involved: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which affects extranodal sites (most often stomach, lung, skin, and ocular adnexa); nodal marginal zone B-cell lymphoma, which affects lymph nodes without evidence of extranodal disease; and splenic marginal zone B-cell lymphoma, which affects the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9C05-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C663E7A-09F5-0AFE-E053-F662850AD265","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-17","modifiedBy":"ONEDATA","dateModified":"2018-05-17","deletedIndicator":"No"},{"value":"Follicular lymphoma","valueDescription":"Follicular Lymphoma","ValueMeaning":{"publicId":"3088584","version":"1","preferredName":"Follicular Lymphoma","longName":"3088584","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D19B-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C663E7A-09FF-0AFE-E053-F662850AD265","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-17","modifiedBy":"ONEDATA","dateModified":"2018-05-17","deletedIndicator":"No"},{"value":"Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma","valueDescription":"Lymphoplasmacytic Lymphoma","ValueMeaning":{"publicId":"2629954","version":"1","preferredName":"Lymphoplasmacytic Lymphoma","longName":"2629954","preferredDefinition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoplasmacytic Lymphoma","conceptCode":"C3212","definition":"A clonal neoplasm of small B-lymphocytes, lymphoplasmacytoid cells, and plasma cells involving the bone marrow, lymph nodes, and the spleen. The majority of patients have a serum IgM paraprotein.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2E665ACD-9834-52CE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-18","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2007-04-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Added NCIt concept.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C7739E8-61EC-391C-E053-F662850AF72E","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-18","modifiedBy":"ONEDATA","dateModified":"2018-05-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6293817","version":"1","preferredName":"Indolent Non-Hodgkin Lymphoma Name","preferredDefinition":"A non-Hodgkin lymphoma with an indolent clinical course. Representative examples include grade 1 and grade 2 follicular lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma.:The words or language units by which a thing is known.","longName":"C8504:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indolent Non-Hodgkin Lymphoma","conceptCode":"C8504","definition":"A non-Hodgkin lymphoma with an indolent clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C663E7A-0998-0AFE-E053-F662850AD265","latestVersionIndicator":"Yes","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-17","modifiedBy":"ONEDATA","dateModified":"2018-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C663E7A-09A9-0AFE-E053-F662850AD265","latestVersionIndicator":"Yes","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-17","modifiedBy":"TAYLORT","dateModified":"2018-05-21","changeDescription":"5/17/17 tt/10126 & 10106.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"DLBL0104","type":"OID, Theradex","context":"Theradex"}],"ReferenceDocuments":[{"name":"What was underlying indolent","type":"Preferred Question Text","description":"What was underlying indolent lymphoma?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C67C739-CD24-0C40-E053-F662850A946C","latestVersionIndicator":"Yes","beginDate":"2018-05-17","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-05-17","modifiedBy":"SOKKERL","dateModified":"2023-12-04","changeDescription":"5/17/18 tt/10106 & 10126.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}